Biotechnology startups that filed an SEC Form D

WhoFiled tracks 502 Biotechnology companies that disclosed a raise through an SEC Form D filing, most recently on November 12, 2026. Each entry links to the full Form D filing detail, reported amount and round stage.

Recent Biotechnology Form D filings

  • Ventoux Biosciences, Inc — SEC Form D filed November 12, 2026, $95K reported.
  • ABVC BIOPHARMA, INC. — SEC Form D filed November 10, 2026, $3.39M reported, Series B+.
  • SUTOL BIO, Inc. — SEC Form D filed November 10, 2026, $474K reported, Seed.
  • Drizzle Health, LLC — SEC Form D filed November 10, 2026, $600K reported, Pre-seed because Drizzle Health raised $600,000 via a simple agreement for future equity to fund initial technology validation..
  • Zai Lab Ltd — SEC Form D filed November 9, 2026, $249.93M reported, Series B+.
  • CARI Health, Inc. — SEC Form D filed November 6, 2026, $280K reported, Seed stage due to raising $280,000 via convertible notes alongside significant non-dilutive grant funding to advance clinical development..
  • Informuta, Inc. — SEC Form D filed November 5, 2026, $713K reported, Seed.
  • BlueHealer Inc. — SEC Form D filed November 4, 2026, $1 reported, Pre-seed, as BlueHealer was incorporated in 2024 and has relied primarily on initial non-dilutive grant funding alongside a nominal equity filing..
  • AI3 Bio, Inc. — SEC Form D filed November 4, 2026, Series A.
  • Ausel, Inc. — SEC Form D filed November 4, 2026, $120K reported, Pre-seed stage based on an initial $120,000 raised toward a broader $5 million target offering..
  • Rgenta Therapeutics, Inc. — SEC Form D filed November 3, 2026, $41.85M reported, Series B+.
  • EVIA Life Sciences Inc. — SEC Form D filed November 2, 2026, $700K reported, Seed stage based on raising $700,002 to scale early commercial manufacturing of its novel formulation portfolio..
  • 511 Therapeutics, Inc. — SEC Form D filed October 30, 2026, $500K reported, Pre-seed due to the $500,000 funding round intended for initial preclinical target validation and early lab operations..
  • Palimpsest Bio Corp. — SEC Form D filed October 30, 2026, $172K reported, Pre-seed phase given the preliminary $172,000 capital raised via a SAFE instrument to initiate foundational drug discovery operations..
  • Synomis, Inc. — SEC Form D filed October 30, 2026, $30K reported, Pre-seed, given the small initial capital raise of $30,000 to cover early entity formation and initial proof-of-concept work..
  • Tru Singular Health, Inc. — SEC Form D filed October 30, 2026, $1.00M reported, Seed stage based on the $1,000,000 raised via Simple Agreements for Future Equity to fund early technical development..
  • Swep Bio, Inc. — SEC Form D filed October 29, 2026, $2.50M reported, Seed stage, as Swep Bio has raised $2.5 million of an initial equity offering to support early R&D and foundational operations..
  • GRIP Molecular Technologies Inc. — SEC Form D filed October 29, 2026, $11.79M reported, Seed.
  • Accufy Diagnostics, Inc. — SEC Form D filed October 28, 2026, $2.00M reported, Seed, as raising $2,000,000 through an equity offering typically corresponds to early-stage diagnostic development and platform validation..
  • TCM Life Science Inc. — SEC Form D filed October 26, 2026, $17K reported, Pre-seed because the $16,666 raise represents initial formation capital for foundational administrative and preliminary laboratory setup..
  • Gut-Brain-Axis Therapeutics Inc. — SEC Form D filed October 26, 2026, $1.97M reported, Series B+.
  • BigHat Biosciences, Inc. — SEC Form D filed October 26, 2026, $75.14M reported, Series B+.
  • OrthoIQ, Inc. — SEC Form D filed October 23, 2026, $1.08M reported, Seed stage, as evidenced by a $1.08 million convertible debt raise intended to fund early product development and clinical validation..
  • Warp Sciences Inc. — SEC Form D filed October 23, 2026, $194.61M reported, Series A.
  • Medical 21, Inc. — SEC Form D filed October 22, 2026, $550K reported, Seed stage based on the small $550,000 equity financing round intended for preliminary development and regulatory filing preparations..
  • Key Proteo, Inc. — SEC Form D filed October 22, 2026, $2.33M reported, Seed.
  • LeanBio Therapeutics, Inc. — SEC Form D filed October 22, 2026, Seed, as the company is leveraging SEC Rule 506(b) equity financing to establish early operational capacity and expand service offerings..
  • Model Medicines, Inc. — SEC Form D filed October 21, 2026, $5.12M reported, Series A.
  • Crosslink Therapeutics Inc. — SEC Form D filed October 20, 2026, $5.50M reported, Seed.
  • Alercell Inc — SEC Form D filed October 19, 2026, $35K reported, Series A.
  • Estuary Biotherapeutics, Inc. — SEC Form D filed October 16, 2026, $40.65M reported, Series A, aligned with the company's launch backed by a $93 million Series A commitment to advance early candidates into the clinic..
  • Immuno Cancer Biotherapeutics, Inc. — SEC Form D filed October 15, 2026, $75K reported, Pre-Seed.
  • Myris Therapeutics, Inc. — SEC Form D filed October 14, 2026, $500K reported, Pre-Seed.
  • Kaigene, Inc. — SEC Form D filed October 14, 2026, $54.96M reported, Series B+.
  • Hypercell Technologies Inc. — SEC Form D filed October 14, 2026, $2.96M reported, Seed, as a $3.0 million equity offering is the standard size for early-stage biotechnology commercialization and field validation..
  • Axelyf, Inc. — SEC Form D filed October 13, 2026, $2.63M reported.
  • Thetis Pharmaceuticals LLC — SEC Form D filed October 13, 2026, $560K reported, Series B+.
  • CURADEL SURGICAL INNOVATIONS, INC. — SEC Form D filed October 13, 2026, $49.84M reported, Series A.
  • OncoNano Medicine, Inc. — SEC Form D filed October 8, 2026, $10.05M reported, Series B due to securing a $10M equity round to advance clinical trial pipelines for its lead surgical imaging agent..
  • Hydregen Ltd — SEC Form D filed October 6, 2026, $1.94M reported, Seed.
  • Toggle Bio — SEC Form D filed October 6, 2026, $200K reported, Pre-seed because a $200,000 raise via SAFEs is typical for early-stage proof-of-concept and initial IP filing in biotechnology..
  • EIKONOKLASTES THERAPEUTICS, INC. — SEC Form D filed October 5, 2026, $16.06M reported, Seed.
  • Zonaliz, Inc. — SEC Form D filed October 5, 2026, $2.50M reported, Seed stage is inferred because a $2.5 million SAFE raise with no revenues is highly characteristic of an early-stage biotechnology company securing initial capital for preclinical development..
  • Altay Therapeutics, Inc. — SEC Form D filed October 2, 2026, $15.74M reported, Seed.
  • CAD Therapeutics, Inc. — SEC Form D filed October 2, 2026, $4.00M reported, Series A because the company raised $4,000,000 through the issuance of Series A common stock to fund its early-stage clinical development..
  • Renovare Therapeutics, Inc. — SEC Form D filed October 2, 2026, $100K reported, Pre-Seed.
  • REVBIO, INC. — SEC Form D filed October 2, 2026, $14.99M reported, Series B+.
  • Vetmab Biosciences, Inc. — SEC Form D filed September 29, 2026, $11.44M reported, Series A, as an $11.4 million equity raise is the standard size for a biotechnology company advancing from preclinical research into veterinary clinical trials..
  • GT Biopharma, Inc. — SEC Form D filed September 29, 2026, $7.75M reported, Series B+.
  • Xact Bio, Inc. — SEC Form D filed September 28, 2026, $10.00M reported, Series A, given that a $10M equity round aligns with standard early-stage biotechnology financing for preclinical development..
  • Q-Immune, Inc. — SEC Form D filed September 28, 2026, $25K reported, Seed.
  • Evia Bio, Inc. — SEC Form D filed September 28, 2026, $5.45M reported, Series A, as a $5.4 million raise is the typical size for an early-stage biotechnology company transitioning from laboratory formulation to commercial scaling and clinical validation..
  • Vertical Longevity Pharmaceuticals, Inc. — SEC Form D filed September 26, 2026, $110K reported, Seed.
  • Navigator Medicines, Inc. — SEC Form D filed September 25, 2026, $10.00M reported, Series A because a ten million dollar raise in the biotechnology sector typically funds the transition from preclinical target validation to IND-enabling studies..
  • Pictura Bio US, Inc. — SEC Form D filed September 25, 2026, $9.13M reported, Seed.
  • Argonaute RNA Ltd — SEC Form D filed September 24, 2026, $1.80M reported, Seed.
  • Uvantis Therapeutics, Inc. — SEC Form D filed September 23, 2026, Seed stage due to an early-stage equity offering of up to $5 million filed on SEC Form D..
  • Caspian Therapeutics, Inc. — SEC Form D filed September 23, 2026, $50.00M reported, Series B+.
  • Pierrepont Therapeutics, Inc. — SEC Form D filed September 22, 2026, $2.41M reported.
  • Opus Medical Therapies, LLC — SEC Form D filed September 22, 2026, $485K reported, Seed stage, as a sub-half-million-dollar equity raise represents an early-stage capital injection typical of initial formulation and preclinical validation phases..
  • Navion Neurosciences Inc. — SEC Form D filed September 22, 2026, $1.95M reported, Seed.
  • Avery Therapeutics, Inc. — SEC Form D filed September 21, 2026, $8.47M reported, Pre-Seed.
  • Typewriter Therapeutics, Inc. — SEC Form D filed September 21, 2026, $56.30M reported, Series A because a $56.3 million equity raise is the standard size for an early-stage biotechnology company transitioning from platform validation to preclinical development..
  • Lexaria Bioscience Corp. (LEXX) — SEC Form D filed September 21, 2026, $113K reported, Growth stage, as indicated by the company's established revenue of over five million dollars and a small, opportunistic capital raise of one hundred thirteen thousand dollars..
  • CERENOME, INC. — SEC Form D filed September 18, 2026, $3.00M reported, Series B+.
  • Aqur Biosciences, Inc. — SEC Form D filed September 18, 2026, $1.50M reported.
  • 3Helix, Inc. — SEC Form D filed September 18, 2026, $7.84M reported.
  • Gliknik Inc — SEC Form D filed September 17, 2026, $15.00M reported, Series B+.
  • Hexamer Therapeutics, Inc — SEC Form D filed September 15, 2026, $500K reported, Seed.
  • Moonwalk Biosciences, Inc. — SEC Form D filed September 14, 2026, $60.00M reported, Series B+.
  • Tempo Therapeutics, Inc. — SEC Form D filed September 11, 2026, $14.00M reported, Pre-Seed.
  • Amplica Bio, Inc. — SEC Form D filed September 11, 2026, $30K reported, Series B+.
  • Retham Technologies, Inc. — SEC Form D filed September 11, 2026, $1.06M reported.
  • seqWell Inc. — SEC Form D filed September 10, 2026, $960K reported.
  • BioLineRx Ltd. (BLRX) — SEC Form D filed September 9, 2026, $3.75M reported, Series B+.
  • Cloverleaf Bio, Inc. — SEC Form D filed September 8, 2026, $14.80M reported, Seed.
  • Pluri Inc. — SEC Form D filed September 4, 2026, $3.68M reported, Series A because a $3.6 million raise represents an early-stage institutional round typical for advancing preclinical biotech assets toward clinical trials..
  • JUPITER NEUROSCIENCES, INC. — SEC Form D filed September 4, 2026, $775K reported, Pre-Seed.
  • Episteme Prognostics, Inc. — SEC Form D filed September 4, 2026, $5.09M reported, Series A, inferred from the $5.09 million raised which represents a typical early-institutional round size required to fund clinical validation studies in the biotechnology sector..
  • Gossamer Bio, Inc. — SEC Form D filed September 4, 2026, $25.00M reported, Series B+.
  • Superluminal Medicines, Inc. — SEC Form D filed September 3, 2026, $65.48M reported, Series B+.
  • Sensible Biotechnologies, Inc. — SEC Form D filed September 2, 2026, $13.52M reported, Seed.
  • Aclarity Genomics, Inc. — SEC Form D filed September 2, 2026, $4.63M reported.
  • Voxcell BioInnovation Inc. — SEC Form D filed September 1, 2026, $2.20M reported, Pre-Seed.
  • MedeSol Global, Inc. — SEC Form D filed August 31, 2026, $25K reported, Seed.
  • Orthobond Corp — SEC Form D filed August 31, 2026, $8.35M reported, Seed.
  • Plowshare Therapies LLC — SEC Form D filed August 28, 2026, $6.65M reported, Pre-Seed.
  • Platform Therapeutics, Inc. — SEC Form D filed August 27, 2026, $1.75M reported, Seed stage because a $1.75 million equity raise is typical for early-stage biotechnology companies validating their initial platform technology..
  • FluidForm Bio, Inc. — SEC Form D filed August 27, 2026, $1.70M reported, Seed, as the amount raised of $1,703,371 is typical for early-stage biotechnology companies developing foundational technology..
  • Noveome Biotherapeutics, Inc. — SEC Form D filed August 27, 2026, $6.75M reported, Series B+.
  • Candor Therapeutics Inc. — SEC Form D filed August 27, 2026, $50K reported, Seed.
  • Codebreaker Tx, Inc. — SEC Form D filed August 26, 2026, $5.88M reported, Seed.
  • Epicrispr Biotechnologies, Inc. — SEC Form D filed August 26, 2026, $176.75M reported, Series C.
  • Aptevo Therapeutics Inc. — SEC Form D filed August 26, 2026, $3.47M reported.
  • Turn Therapeutics Inc. — SEC Form D filed August 26, 2026, $1.65M reported.
  • ProEncia Biotechnology Inc. — SEC Form D filed August 26, 2026, $1.51M reported.
  • UBIVAC, INC. — SEC Form D filed August 26, 2026, $80K reported, Series B+.
  • MalarVx, Inc. — SEC Form D filed August 25, 2026, $125K reported.
  • Axiom Therapeutics Inc. — SEC Form D filed August 25, 2026, Seed.
  • Unravel Biosciences, Inc. — SEC Form D filed August 24, 2026, $4.10M reported, Seed.

Showing the 100 most recent of 502 Biotechnology Form D filings tracked by WhoFiled.

Other sectors